Literature DB >> 12003431

Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy.

Matthieu Allez1, Marc Lemann, Joëlle Bonnet, Pierre Cattan, Raymond Jian, Robert Modigliani.   

Abstract

OBJECTIVE: Prediction of the clinical course of Crohn's disease (CD) is difficult in the long term. Our aim was to determine whether the presence of severe endoscopic lesions (SELs) may predict a higher risk of colectomy and penetrating complications.
METHODS: All patients at our institution with active ileocoIonic CD who had colonoscopies between 1990 and 1996 were included in the study. SELs were defined as extensive and deep ulcerations covering more than 10% of the mucosal area of at least one segment of the colon.
RESULTS: Among the 102 patients included, 53 had SELs at index colonoscopy. During the follow-up (median = 52 months), 37 patients underwent colonic resection. Probabilities of colectomy at 1, 3, and 8 yr were 20%, 26%, and 42%. Risk of colectomy was independently affected by the presence of SELs at index colonoscopy (relative risk [RR] = 5.43, 95% CI = 2.64-11.18), a Crohn's Disease Activity Index level greater than 288 (RR = 2.21, 95% CI = 1.09-4.47), and the absence of immunosuppressive therapy during the follow-up (RR = 2.44, 95% CI = 1.20-5.00). Probabilities of colectomy were, respectively, 31% and 6% at 1 yr, 42% and 8% at 3 yr, and 62% and 18% at 8 yr in patients with and without SELs. We performed a second analysis excluding the 14 patients operated on within the 3 months after the index colonoscopy: presence of SELs remained the only significant factor predictive of colectomy (RR = 6.72, 95% CI = 2.26-20.03). All six patients with penetrating complications during the follow-up had SELs at index colonoscopy.
CONCLUSIONS: Patients with CD exhibiting deep and extensive ulcerations at colonoscopy have a more aggressive clinical course with an increased rate of penetrating complications and surgery.

Entities:  

Mesh:

Year:  2002        PMID: 12003431     DOI: 10.1111/j.1572-0241.2002.05614.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  66 in total

Review 1.  Role of endoscopy in predicting the disease course in inflammatory bowel disease.

Authors:  Matthieu Allez; Marc Lémann
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

2.  Tailoring the treatment to the individual in Crohn's disease.

Authors:  Edouard Louis; Jacques Belaiche; Catherine Reenaers
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

3.  Optimal use of biologics in the management of Crohn's disease.

Authors:  Remo Panaccione; Subrata Ghosh
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

Review 4.  Mucosal healing in inflammatory bowel disease: where do we stand?

Authors:  Christina Ha; Asher Kornbluth
Journal:  Curr Gastroenterol Rep       Date:  2010-12

Review 5.  Assessment of stricturing Crohn's disease: Current clinical practice and future avenues.

Authors:  Dominik Bettenworth; Tobias M Nowacki; Friederike Cordes; Boris Buerke; Frank Lenze
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 6.  Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.

Authors:  Britt Christensen; David T Rubin
Journal:  Curr Gastroenterol Rep       Date:  2016-01

Review 7.  The Role of Early Biologic Therapy in Inflammatory Bowel Disease.

Authors:  Dana Rachel Berg; Jean-Frederic Colombel; Ryan Ungaro
Journal:  Inflamm Bowel Dis       Date:  2019-11-14       Impact factor: 5.325

8.  The role of mucosal healing in the treatment of patients with inflammatory bowel disease.

Authors:  Byron P Vaughn; Sveta Shah; Adam S Cheifetz
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

Review 9.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

10.  Immunomodulation does not alter histology in resected Crohn's disease.

Authors:  F A Frizelle; A Ing; R B Gearry; M Whitehead; I G Faragher; B Dobbs
Journal:  Tech Coloproctol       Date:  2009-09-23       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.